Zydus Lifesciences Q1 Results FY27: Uniresearch Prediction and Analysis

June 25, 2026
Posted by: Ankit Jaiswal
Category: News

Zydus Lifesciences Q1 Results FY27: Uniresearch projects Revenue Rs 6,962 Cr | PAT Rs 1,561 Cr (Uniresearch trailing analysis). Q4 FY26: Rev Rs 7,587 Cr | PAT Rs 1,341 Cr.

Zydus Lifesciences Q1 Results FY27 outlook from Uniresearch is anchored on verified Q4 FY26 actuals and Uniresearch trailing analysis. Uniresearch projects Zydus Lifesciences Q1 FY27 Revenue Rs 6,962 Cr (+5.9% YoY) and PAT Rs 1,561 Cr (+2.6% YoY). Prepared by Ankit Jaiswal.

Click Here – Get Free Investment Predictions

Table of Contents

Zydus Lifesciences Q1 Results FY27 – Uniresearch Prediction

Metric	Q1 FY26 Actual	Q1 FY27 Uniresearch Prediction	YoY Change	Source
Zydus Lifesciences Revenue (Rs Cr)	6,574	6,962	+5.9%	Uniresearch \| Uniresearch trailing analysis
PAT (Rs Cr)	1,521	1,561	+2.6%	Uniresearch \| Uniresearch trailing analysis
Avg Analyst Target	See screener	12-month view	–	Uniresearch trailing analysis

Zydus Lifesciences Q4 FY26 Performance

Metric	Q4 FY26 Actual	vs Q1 FY26	Source
Revenue (Rs Cr)	7,587	+15.4%	Screener consolidated
PAT (Rs Cr)	1,341	-11.8%	Screener consolidated

Analyst Views and Growth Outlook

The Uniresearch trailing analysis projects Zydus Lifesciences FY27 revenue at +5.9% and profit at +2.6% YoY. Uniresearch applied these growth rates to Q1 FY26 actuals to derive the Q1 FY27 prediction. Q4 FY26 actuals showed Zydus Lifesciences delivering revenue of Rs 7,587 Cr and PAT of Rs 1,341 Cr.

Key Watchpoints

Revenue Delivery

Key question: can Zydus Lifesciences reach Rs 6,962 Cr in Q1 FY27 revenue, representing +5.9% YoY growth over the Q1 FY26 base of Rs 6,574 Cr.

PAT vs Growth Target

Profit performance of Rs 1,561 Cr (+2.6%) vs the Q1 FY26 base of Rs 1,521 Cr is the profitability watchpoint for Zydus Lifesciences in Q1 FY27.

Risks

Revenue Shortfall

Revenue below the +5.9% consensus would indicate sector headwinds or execution delays for Zydus Lifesciences.

Margin Pressure

Cost increases or margin compression could challenge the +2.6% PAT growth projection for Zydus Lifesciences in Q1 FY27.

Conclusion

The Zydus Lifesciences Q1 FY27 Uniresearch projection of Revenue Rs 6,962 Cr and PAT Rs 1,561 Cr is derived from the Uniresearch trailing analysis. Investors should watch Q4 FY26 actuals as the base, and track Zydus Lifesciences live on the Univest Screener.

Track Zydus Lifesciences Live on the Univest Screener

Download the Univest iOS App or Univest Android App for live FY27 alerts.

Disclaimer: Revenue and PAT actuals are sourced from consolidated quarterly financial data. Q1 Results FY27 Uniresearch predictions are derived by applying analyst consensus growth rates to verified Q1 FY26 actuals. These are projections, not guaranteed outcomes. Investments in securities are subject to market risk. For educational purposes only. SEBI RA INH000013776.

FAQs on Zydus Lifesciences Q1 Results FY27

What is Uniresearch’s PAT prediction for Zydus Lifesciences Q1 Results FY27?

Ans. Uniresearch projects Zydus Lifesciences Q1 FY27 PAT at Rs 1,561 Cr (+2.6% vs Q1 FY26 base Rs 1,521 Cr).

What is the Revenue forecast for Zydus Lifesciences Q1 Results FY27?

Ans. Zydus Lifesciences Q1 FY27 Revenue is projected at Rs 6,962 Cr (+5.9% consensus).

What were Zydus Lifesciences Q4 FY26 actuals for Zydus Lifesciences Q1 Results FY27?

Ans. Q4 FY26 Revenue Rs 7,587 Cr and PAT Rs 1,341 Cr.

How many analysts cover Zydus Lifesciences Q1 Results FY27?

Ans. The prediction uses Uniresearch trailing analysis, avg target Rs 0.

What consensus applies to Zydus Lifesciences Q1 Results FY27?

Ans. Revenue +5.9% and profit +2.6% (Uniresearch trailing analysis).

What are the main risks to Zydus Lifesciences Q1 Results FY27?

Ans. Revenue missing +5.9% consensus and PAT pressure vs +2.6% growth target.

What is the Q1 FY26 base for Zydus Lifesciences Q1 Results FY27?

Ans. Q1 FY26 Revenue Rs 6,574 Cr and PAT Rs 1,521 Cr.

News

Author: Ankit Jaiswal

Ankit Jaiswal is the Senior Research Analyst at Univest, leading the platform's in-house equity research desk and serving as the editorial reviewer for all research and blog content published at univest.in. With 11+ years of experience in Indian equity markets, he oversees stock recommendations, earnings analysis, sector coverage, and ensures every published article meets SEBI Research Analyst Regulations. He holds a Bachelor of Commerce (B.Com) from St. Xavier's College, Kolkata — one of India's most prestigious commerce institutions — and has cleared CMT Level 2 from the CMT Association, a globally recognised certification in technical analysis and market research. His research methodology combines fundamental analysis (earnings quality, balance sheet strength, management commentary) with advanced technical analysis (chart patterns, momentum indicators, market structure) — giving Univest's retail investors a dual-lens approach that most Indian research platforms lack. Ankit is among the most comprehensively certified analysts in Indian financial media, holding five NISM certifications: Series-XV (Research Analyst), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-VI (Depository Operations), and Series-V-A (Mutual Fund Distributors). At Univest — India's SEBI-registered research and advisory platform — Ankit's responsibilities include leading the research team, finalising stock recommendations published across Pro Lite, Pro Super, and Pro Gold advisory services, and maintaining editorial oversight of all YMYL financial content published on the blog.